Ronan MacLoughlinDr Ronan MacLoughlin, PhD MBS, is currently director of Research and Development, Science and Emerging Technologies in Aerogen limited and Irish medical device company specializing in respiratory drug delivery. He has more than 25 years of experiencein the design and development of aerosol drug delivery systems and drug/device combination products. He currently has more than 120 articles, and multiple conference presentations and conference papers combined with several patents. He holds the position of adjunct associate professor in Trinity College Dublin’s (Ireland) Department of Pharmaceutics and Pharmaceutical Technology, honorary Senior Lecturer in the Royal College of Surgeons Ireland (RCSI), nonexecutive director on the board of several startup and scaling Med tech and pharmaceutical companies. Additionally, he is currently chair of the pediatric and cystic fibrosis working group within the International Society for aerosols in medicine. In 2024 he was honored with the Thomas T Mercer award, recognizing Dr MacLoughlin’s excellence in the areas of pharmaceutical aerosols and inhalable materials.development of drug delivery systems and drug device combinations, he has >220 collaborative publications,
as well as 12 granted patents.

His most recent focus has been on enabling several clinical programs making use of aerosolised prophylactics
and therapeutics for COVID-19, and his work on delivery of inhaled vaccines has resulted in the
world’s first approval for an orally inhaled vaccine for COVID-19 (Convidecia Air). His contribution to the
state of the art in fugitive medical and patient-derived aerosols was central to the evolution of several
critical care consensus statements around the safe use of aerosol therapy during the COVID-19 pandemic. Read More Read Less